AEON is developing ABP-450, a proprietary botulinum toxin, to unlock the promise of therapeutic botulinum toxin to treat nervous system-related conditions
Investors 1
| Date | Name | Website |
| 19.05.2024 | Longitude ... | longitudec... |
Mentions in press and media 1
| Date | Title | Description |
| 23.09.2022 | Pfizer and Sangamo re-open PhIII of hemophilia A gene therapy; AEON headed to PhIII | A year after voluntarily pausing the Phase III study of their hemophilia A gene therapy program, and four months after FDA lifted the clinical hold, Pfizer and Sangamo Therapeutics say they will resume dosing next mon... |